# reload+after+2024-01-23 04:45:28.766750
address1§1350 Old Bayshore Highway
address2§Suite 400
city§Burlingame
state§CA
zip§94010
country§United States
phone§650 238 9600
website§https://www.inva.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
fullTimeEmployees§101
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Pavel  Raifeld C.F.A.', 'age': 39, 'title': 'Chief Executive Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 754666, 'exercisedValue': 0, 'unexercisedValue': 3000}, {'maxAge': 1, 'name': 'Ms. Marianne  Zhen CPA', 'age': 54, 'title': 'Chief Accounting Officer & Secretary', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 530209, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen  Basso M.B.A.', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§5
shareHolderRightsRisk§4
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1441670400
payoutRatio§0.0
beta§0.554
priceToSalesTrailing12Months§3.6586173
currency§USD
dateShortInterest§1702598400
forwardEps§0.82
pegRatio§0.52
exchange§NMS
quoteType§EQUITY
shortName§Innoviva, Inc.
longName§Innoviva, Inc.
firstTradeDateEpochUtc§1096983000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7fee3656-d883-3b1c-8337-4a733b67dfef
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§15.0
targetMeanPrice§15.0
targetMedianPrice§15.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§6.847
earningsGrowth§-0.649
grossMargins§0.77709
ebitdaMargins§0.48797
trailingPegRatio§None
